{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-026761","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.532165+00:00","generated_at":"2026-05-15T13:50:57.023526+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Century Therapeutics FY2025 net loss $9.6M; $135M placement extends cash into Q1 2029","bullets":["Net loss of $9.6M improved from $126.6M in 2024; collaboration revenue from BMS rose to $109.2M (from $6.6M).","Cash, cash equivalents, and securities $117.1M at Dec 31, 2025; with $135M Jan 2026 placement, runway extended to Q1 2029.","CNTY-813 (T1D beta islet therapy) IND submission expected Q4 2026; initial clinical data anticipated 2H 2027.","CNTY-308 (CD19-targeted CAR-iT) on track for clinical entry in 2026; CARAMEL IST data expected later this year.","Strengthened balance sheet via oversubscribed $135M private placement led by TCGX; new board members appointed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-026761","json":"https://secwatch.observer/filing/0001104659-26-026761.json","markdown":"https://secwatch.observer/filing/0001104659-26-026761.md","text":"https://secwatch.observer/filing/0001104659-26-026761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926026761/0001104659-26-026761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926026761/tm268574d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:50:57.023526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"760f58244aa040970879e7099bfcc23e3a7544cd","claim":"Century Therapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $109.2 million.","evidence_excerpt":"first quarter of 2029. · Collaboration Revenue: Collaboration revenue generated through the company’s collaboration, option, and license agreement with Bristol-Myers Squibb was $109.2 million for the year ended December 31, 2025, compared to $6.6 million for the same period in 2024. · Research and Development (R&D) Expenses: R&D expenses were $95.7 million for the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926026761/0001104659-26-026761-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Revenue","value":"$109.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}